Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease

Circ Res. 2018 Aug 17;123(5):590-600. doi: 10.1161/CIRCRESAHA.118.311134.

Abstract

Hydrogen sulfide (H2S)-a potent gaseous signaling molecule-has emerged as a critical regulator of cardiovascular homeostasis. H2S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H2S-donating agents and the genetic manipulation of H2S-producing enzymes have revealed multiple beneficial effects of H2S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H2S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H2S-mediated signaling pathways. This review will discuss recently developed H2S therapeutics, introduce signaling pathways that are influenced by H2S-dependent sulfhydration, and explore the dual-protective effect of H2S in cardiorenal syndrome.

Keywords: animals; cardiovascular diseases; nitric oxide.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Humans
  • Hydrogen Sulfide / metabolism
  • Hydrogen Sulfide / therapeutic use*
  • Protein Processing, Post-Translational
  • Signal Transduction

Substances

  • Hydrogen Sulfide